Bernstein Liebhard LLP is investigating SES AI Corporation's directors and officers for potential breaches of fiduciary duties related to the company. The investigation targets shareholders who purchased SES AI stock before January 29, 2025. Investors holding SES AI shares are encouraged to contact the law firm to discuss their legal rights and options. This investigation could lead to legal action if misconduct is confirmed, impacting the company's governance and shareholder value.
IDEAYA Biosciences berencana untuk memulai uji coba klinis Fase 3 untuk IDE849, obat kanker paru-paru sel kecil stadium lanjut (ES-SCLC), pada akhir tahun 2026. Keputusan ini menyusul pertemuan positif dengan FDA mengenai desain uji coba. Uji coba in...
Oppenheimer & Co. Inc. announced that Joel Berry II, a former college basketball star and professional player, has joined its Robinson Private Client Group as a Financial Advisor. Berry will focus on advising current and former athletes, including st...
So-Young International Inc. posted a 33.4% increase in total revenues to RMB505.2 million in Q2 2026, led by a 129.5% surge in aesthetic treatment services revenue. The company narrowed its net loss to RMB22.7 million from RMB36.0 million a year earl...
Primary Hydrogen Corp. has secured four exploration licences totaling 1,101 hectares for the Wallace Natural Hydrogen Project in Nova Scotia's Cumberland Basin, expanding its holdings to six licences in the area. The project area includes significant...
Jazz Pharmaceuticals announced positive results from its HERIZON-GEA-01 trial, showing that Ziihera, combined with chemotherapy, significantly improved overall survival in adults with HER2-positive gastroesophageal adenocarcinoma (GEA) compared to th...
